Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI Tool Identifies and Distinguishes Between Difficult-to-Diagnose Cardiac Conditions on Echocardiograms

By HospiMedica International staff writers
Posted on 07 Apr 2023

Identifying hypertrophic cardiomyopathy and cardiac amyloidosis, two critical heart conditions can be quite challenging, even for seasoned cardiologists, resulting in patients waiting years to decades before receiving an accurate diagnosis. More...

Without comprehensive testing, differentiating between these conditions and changes in heart shape and size that may be associated with normal aging can be perplexing for cardiologists. Notably, in the initial stages of the disease, both of these cardiac conditions can resemble the appearance of a heart that has aged and progressed naturally without any disease. Now, for the first time, an algorithm can spot these difficult-to-diagnose cardiac conditions.

Deposits of abnormal protein (amyloid) in heart tissue cause cardiac amyloidosis, also known as "stiff heart syndrome." These deposits replace healthy heart muscle, making it difficult for the heart to function correctly. Hypertrophic cardiomyopathy, on the other hand, causes the heart muscle to thicken and stiffen, leading to inadequate relaxation and blood filling, which can result in heart valve damage, fluid buildup in the lungs, and irregular heart rhythms. Physician-scientists at the Smidt Heart Institute at Cedars-Sinai (Los Angeles, CA, USA) have developed an artificial intelligence (AI) tool that can differentiate between these two life-threatening heart conditions effectively. The novel, two-step algorithm analyzed more than 34,000 cardiac ultrasound videos from Cedars-Sinai and Stanford Healthcare's echocardiography laboratories. The algorithm identified particular features related to heart wall thickness and chamber size and flagged patients who were suspicious of having these potentially unrecognized cardiac conditions.

The AI algorithm not only accurately distinguishes abnormal from normal cardiac conditions but can also identify which potentially life-threatening heart diseases may be present. It provides warning signals that can detect the disease well before it progresses to a stage that can impact health outcomes. With earlier diagnosis, patients can receive effective treatment sooner, prevent adverse clinical events, and improve their quality of life. The researchers hope that the technology will be utilized to identify patients at an early stage of the disease, as earlier diagnosis enables the most benefit from available therapies that can prevent the worst outcomes such as hospitalizations, heart failure, and sudden death.

“Our AI algorithm can pinpoint disease patterns that can’t be seen by the naked eye, and then use these patterns to predict the right diagnosis,” said David Ouyang, MD, a cardiologist in the Smidt Heart Institute and senior author of the study.

“One of the most important aspects of this AI technology is not only the ability to distinguish abnormal from normal, but also to distinguish between these abnormal conditions, because the treatment and management of each cardiac disease is very different,” added Susan Cheng, MD, MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at the Smidt Heart Institute and co-senior author of the study.

Related Links:
Cedars-Sinai 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.